FDA Clears Quantum BioPharma to Run First Human Efficacy Trial of Its Myelin-Protecting MS Drug
Quantum BioPharma's Lucid-MS targets myelin degradation directly rather than the immune system — a different approach from most existing MS drugs. The FDA cleared the company on August 10 to find out whether it works in actual patients.